Portland, Maine, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Most people believe dementia is a life sentence. Dr. Clint Steele once...
TOKYO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters:Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or...
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio reviewDecision reflects prioritization of higher‑impact opportunities across Genmab’s...
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic...
Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic AlternativesNESS ZIONA, Israel, Dec....
MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential...
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line...
VANCOUVER, British Columbia, Dec. 29, 2025 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (CSE: MBAI) (OTCQB: MBAIF) (FSE: Y30) (the...
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows...
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children...
CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated...
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect...
Next-Generation Novasight Hybrid™ System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing Adoption...
CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE...
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it...
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage...
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the...